Genen­tech beefs up its PD-L1 com­bo pipeline, sign­ing the 'don’t eat me' spe­cial­ists at Forty Sev­en

Af­ter ex­pand­ing its part­ner­ship with Syn­dax $SNDX ear­li­er this week on their lead drug, Genen­tech has beefed up their pipeline of PD-L1 com­bos with a fresh pact with Stan­ford spin­out Forty Sev­en.

The biotech put out word that Genen­tech will com­bine their two check­point drugs for use against acute myeloid leukemia and blad­der can­cer, with the big Roche sub­sidiary spon­sor­ing the stud­ies.

Tecen­triq was the fourth PD-1/L1 check­point to hit the mar­ket, tak­ing one foot off the brake of an im­mune re­sponse tar­get­ing can­cer cells. Forty Sev­en, the brain­child of Stan­ford’s leg­endary in­ves­ti­ga­tor Irv Weiss­man, tar­gets the “don’t eat me” sig­nal can­cer cells em­ploy to hide out from a macrophage as­sault. The drug works by bind­ing Hu5F9-G4 to CD47.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.